{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T03:38:00Z","timestamp":1795145880790,"version":"4.10.3"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:p>\n            The clinical presentation of autonomic failure is orthostatic hypotension. Severely affected patients require pharmacological treatment to prevent presyncopal symptoms or frank syncope. We previously reported in a proof of concept study that pediatric doses of the norepinephrine transporter blockade, atomoxetine, increases blood pressure in autonomic failure patients with residual sympathetic activity compared with placebo. Given that the sympathetic nervous system is maximally activated in the upright position, we hypothesized that atomoxetine would be superior to midodrine, a direct vasoconstrictor, in improving upright blood pressure and orthostatic hypotension\u2013related symptoms. To test this hypothesis, we compared the effect of acute atomoxetine versus midodrine on upright systolic blood pressure and orthostatic symptom scores in 65 patients with severe autonomic failure. There were no differences in seated systolic blood pressure (means difference=0.3 mm Hg; 95% confidence [CI], \u22127.3 to 7.9;\n            <jats:italic>P<\/jats:italic>\n            =0.94). In contrast, atomoxetine produced a greater pressor response in upright systolic blood pressure (means difference=7.5 mm Hg; 95% CI, 0.6 to 15;\n            <jats:italic>P<\/jats:italic>\n            =0.03) compared with midodrine. Furthermore, atomoxetine (means difference=0.4; 95% CI, 0.1 to 0.8;\n            <jats:italic>P<\/jats:italic>\n            =0.02), but not midodrine (means difference=0.5; 95% CI, \u22120.1 to 1.0;\n            <jats:italic>P<\/jats:italic>\n            =0.08), improved orthostatic hypotension\u2013related symptoms as compared with placebo. The results of our study suggest that atomoxetine could be a superior therapeutic option than midodrine for the treatment of orthostatic hypotension in autonomic failure.\n          <\/jats:p>","DOI":"10.1161\/hypertensionaha.114.04225","type":"journal-article","created":{"date-parts":[[2014,9,3]],"date-time":"2014-09-03T05:43:39Z","timestamp":1409723019000},"page":"1235-1240","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":111,"title":["Efficacy of Atomoxetine Versus Midodrine for the Treatment of Orthostatic Hypotension in Autonomic Failure"],"prefix":"10.1161","volume":"64","author":[{"given":"Claudia E.","family":"Ramirez","sequence":"first","affiliation":[{"name":"From the Department of Medicine, Division of Clinical Pharmacology and the Autonomic Dysfunction Center, Vanderbilt University School of Medicine, Nashville, Tennessee (C.E.R., L.E.O., A.C.A., A.G., A.D., S.R.R., D.R., I.B., C.A.S.); and Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee (L.C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E.","family":"Okamoto","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Division of Clinical Pharmacology and the Autonomic Dysfunction Center, Vanderbilt University School of Medicine, Nashville, Tennessee (C.E.R., L.E.O., A.C.A., A.G., A.D., S.R.R., D.R., I.B., C.A.S.); and Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee (L.C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy C.","family":"Arnold","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Division of Clinical Pharmacology and the Autonomic Dysfunction Center, Vanderbilt University School of Medicine, Nashville, Tennessee (C.E.R., L.E.O., A.C.A., A.G., A.D., S.R.R., D.R., I.B., C.A.S.); and Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee (L.C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Gamboa","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Division of Clinical Pharmacology and the Autonomic Dysfunction Center, Vanderbilt University School of Medicine, Nashville, Tennessee (C.E.R., L.E.O., A.C.A., A.G., A.D., S.R.R., D.R., I.B., C.A.S.); and Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee (L.C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Diedrich","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Division of Clinical Pharmacology and the Autonomic Dysfunction Center, Vanderbilt University School of Medicine, Nashville, Tennessee (C.E.R., L.E.O., A.C.A., A.G., A.D., S.R.R., D.R., I.B., C.A.S.); and Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee (L.C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Choi","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Division of Clinical Pharmacology and the Autonomic Dysfunction Center, Vanderbilt University School of Medicine, Nashville, Tennessee (C.E.R., L.E.O., A.C.A., A.G., A.D., S.R.R., D.R., I.B., C.A.S.); and Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee (L.C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish R.","family":"Raj","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Division of Clinical Pharmacology and the Autonomic Dysfunction Center, Vanderbilt University School of Medicine, Nashville, Tennessee (C.E.R., L.E.O., A.C.A., A.G., A.D., S.R.R., D.R., I.B., C.A.S.); and Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee (L.C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Robertson","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Division of Clinical Pharmacology and the Autonomic Dysfunction Center, Vanderbilt University School of Medicine, Nashville, Tennessee (C.E.R., L.E.O., A.C.A., A.G., A.D., S.R.R., D.R., I.B., C.A.S.); and Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee (L.C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Italo","family":"Biaggioni","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Division of Clinical Pharmacology and the Autonomic Dysfunction Center, Vanderbilt University School of Medicine, Nashville, Tennessee (C.E.R., L.E.O., A.C.A., A.G., A.D., S.R.R., D.R., I.B., C.A.S.); and Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee (L.C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyndya A.","family":"Shibao","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Division of Clinical Pharmacology and the Autonomic Dysfunction Center, Vanderbilt University School of Medicine, Nashville, Tennessee (C.E.R., L.E.O., A.C.A., A.G., A.D., S.R.R., D.R., I.B., C.A.S.); and Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee (L.C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01512.x"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2013.04.006"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90230-M"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03540370036033"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.1.120"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1695"},{"key":"e_1_3_3_8_2","volume-title":"FDA Proposes Withdrawal of Low Blood Pressure Drug. US Food and Drug Administration","author":"Walsh S","unstructured":"Walsh SFDA Proposes Withdrawal of Low Blood Pressure Drug. US Food and Drug Administration. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm222580.htm. Accessed April 22, 2013."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200309000-00017"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2011.05.009"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01824986"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.107.089961"},{"key":"e_1_3_3_13_2","first-page":"337","article-title":"Pharmaceutical approval update.","volume":"39","author":"Goldenberg MM","year":"2014","unstructured":"Goldenberg MM. Pharmaceutical approval update. P T. 2014;39:337\u2013344.","journal-title":"P T"},{"key":"e_1_3_3_14_2","first-page":"25","volume-title":"In: Disorders of the Autonomic Nervous System","author":"Mosqueda-Garcia R","year":"1995","unstructured":"Mosqueda-Garcia R. Evaluation of the autonomic nervous system. , Robertson D, Biaggioni I, In: Disorders of the Autonomic Nervous System. London: Harwood Academy Press; 1995:25\u201329."},{"key":"e_1_3_3_15_2","first-page":"86","volume-title":"In: Clinical Diagnostic Manual for the House Officer","author":"Robertson D","year":"1981","unstructured":"Robertson D. Clinical pharmacology: assessment of autonomic function. , Baughman K, Greene B, In: Clinical Diagnostic Manual for the House Officer. Baltimore, MD: William and Wilkins; 1981:86\u2013101."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10286-011-0119-5"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10286-011-0146-2"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1089\/104454603321666199"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1986.101"},{"key":"e_1_3_3_20_2","volume-title":"Chelsea Therapeutics, Inc. NortheraTM (Droxidopa) Advisory Committee Briefing Document. US Food and Drug Administration","unstructured":"Chelsea Therapeutics, Inc. NortheraTM (Droxidopa) Advisory Committee Briefing Document. US Food and Drug Administration. http:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/cardiovascularandrenaldrugsadvisorycommittee\/ucm381155.pdf. Accessed March 11, 2014."},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(90)90005-M"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.4.noc50340"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c332"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.pra.0000400261.45290.bd"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110212"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12062"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.38.6.951"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)80246-0"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2013.08.064"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.29.1.104"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.53.11.994"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2012.01.058"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(84)80264-8"},{"key":"e_1_3_3_34_2","first-page":"123","volume-title":"In: Vascular Neuroeffector Mechanisms","author":"Osswald W","year":"1976","unstructured":"Osswald W. Transmitter disposition mechanisms. , Bevan J, Johansson B, Nedergaard O, In: Vascular Neuroeffector Mechanisms. Basel: Karger; 1976:123\u2013130."},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.0000199982.71858.11"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aws055"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410430205"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1040786"},{"key":"e_1_3_3_39_2","first-page":"491","volume-title":"In: Ethnic Differences in Reaction to Drug and Xenobiotics","author":"Price-Evans D","year":"1986","unstructured":"Price-Evans D. Therapy. , Kalow W, Goedde H, Agarwal D, In: Ethnic Differences in Reaction to Drug and Xenobiotics.New York: Liss; 1986:491\u2013526."}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.114.04225","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T09:49:11Z","timestamp":1715593751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.114.04225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.114.04225"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.114.04225","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"2014-07-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-08-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-09-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}